OncLive TV

Chandler Park, MD, FACP, discusses patient characteristics, disease factors, and drug mechanisms of action that influence treatment decisions in mHSPC.

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Zosia Piotrowska, MD, MHS, discusses the importance of differentiating between HER2 alterations among patients with non–small cell lung cancer.

John H. Strickler, MD, details the rationale for evaluating telisotuzumab adizutecan in advanced gastric/GEJ cancer.

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.

Pedro Barata, MD, discusses electing appropriate testing methods in patients with mCRPC.

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Zosia Piotrowska, MD, MHS, discusses disease factors that guide treatment decision-making and sequencing for patients with HER2-mutated NSCLC.

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Raza Hoda, MD, FASCP, discusses characterizing hormone receptor–positive, HER2-low, -ultralow, and -null breast carcinoma in the metastatic setting.

Armin Ghobadi, MD, discusses the efficacy and safety of WU-CART-007 in heavily pretreated patients with relapsed/refractory T-ALL and LBL.

Timothy S. Fenske, MD, MS, discusses implications for data on the omission of auto-HCT in MCL after first CR and with undetectable MRD.

Yair Lotan, MD, discusses the benefits and complications associated with radical cystectomy for patients with BCG-unresponsive NMIBC.

Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.

Yair Lotan, MD, discusses the evolving treatment paradigm for Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer.

Laura A. Huppert, MD, discusses survival outcomes of patients with metastatic breast cancer and leptomeningeal disease according to disease subtype.

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.

Arvind N. Dasari, MD, MS, discusses the roles for the FDA-approved agents fruquintinib and TAS-102 plus bevacizumab in the mCRC treatment paradigm.

Charles E. Geyer, Jr., MD, discusses the efficacy and safety of perioperative atezolizumab plus chemotherapy in stage II/III triple-negative breast cancer.

Sattva S. Neelapu, MD, discusses a 5-year follow-up data for axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Rory Shallis, MD, discusses the addition of pembrolizumab to azacitidine citidine and venetoclax in patients with acute myeloid leukemia.

Dimitrios Nasioudis, MD, discusses preclinical study findings utilizing XPO1 inhibition for TP53 wild-type low-grade serous and clear cell ovarian cancer.

Patrick Borgen, MD, discusses how advances in artificial intelligence may influence the future of oncology practice.

Patrick I. Borgen, MD, discusses research outlining the current clinical applications and limitations of artificial intelligence in oncology practice.

Elizabeth Brem, MD, discusses data for odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma.

Daniel DeAngelo, MD, PhD, discusses the FDA approval of blinatumomab in the consolidation phase in CD19-positive, Ph-negative B-cell precursor ALL.